朗生醫藥(00503.HK)的股東應佔溢利於2020年達8,820萬元(美元,下同),同比增長3.8倍,而2019年賺1,834萬元相對於2018年的616萬元飙升113倍,業績尚可。朗生經營業務情況方面,核心的醫藥業務收入5,150萬元同比增長1.9%,和分部溢利2,134萬元上升28%,增幅不及2019年分别所達的5.2%與30.7%,在是年受困於新冠肺疫COVID-19的情況底下,屬相當不錯的表現。尤其是該集團在疫情底下控制銷售及分銷開支,使毛利得以提升。
黎偉成:朗生醫藥(00503.HK)醫藥業務增收多賺 自營專科藥產品平穩增長
1970-01-01T00:00:00-05:00January 1st, 1970|
Related Posts
-
Japan launches $6bn-plus space fund to bolster private ventures
April 26th, 2024 -
Shanghai presses ahead into secondary market with new 10b yuan fund
April 26th, 2024 -
Government allows plastic use for pre-packaged food, takeaways
April 26th, 2024 -
Emirates launches aircraft engineer recruitment drive in Hong Kong
April 26th, 2024